Loading
Everything in development, the open problems and what is being done about them, the roadmaps, and what changed on this record.
What is in development for Advanced hepatocellular carcinoma (BCLC C), drawn from the whole corpus: 51 items. Drugs are grouped by the most advanced trial phase they have reached anywhere; approved treatments sit under standard of care. Technologies are the methods being tested for this cancer, trials are the studies recorded here, and ideas are proposals not yet in a trial.
No trial has defined the best drug after progression on immunotherapy.
Nothing recorded yet.
Nothing recorded yet.
Also on OnCo: Resistance atlas · Lines of therapy.
Patients with Child-Pugh B liver function are excluded from trials yet make up a large share of the clinic.
Non-viral (metabolic) HCC may benefit less from immunotherapy, and the reason is unclear.
Dated changes read from the records linked to this cancer: approvals, regulatory steps, reported trials, guideline versions and milestones. Newest first; no date is inferred.
On EdgeAll 15 changes by month →When this page itself was last checked or edited.
A milestone in how this cancer is treated.
OS 23.
OS HR 0.
A milestone in how this cancer is treated.
OS 19.